Nevro (NVRO) Competitors

Nevro (NYSE:NVRO) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.

Does the MarketBeat Community believe in NVRO or BVS?

Nevro received 474 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 62.92% of users gave Nevro an outperform vote while only 62.50% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Nevro	Outperform Votes 504 62.92%	Underperform Votes 297 37.08%
Bioventus	Outperform Votes 30 62.50%	Underperform Votes 18 37.50%

Do insiders & institutionals have more ownership in NVRO or BVS?

95.5% of Nevro shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 3.2% of Nevro shares are held by company insiders. Comparatively, 32.9% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer NVRO or BVS?

In the previous week, Nevro had 2 more articles in the media than Bioventus. MarketBeat recorded 8 mentions for Nevro and 6 mentions for Bioventus. Bioventus' average media sentiment score of 0.70 beat Nevro's score of 0.00 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nevro	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer NVRO or BVS?

Nevro currently has a consensus price target of $6.43, indicating a potential upside of 12.03%. Bioventus has a consensus price target of $15.00, indicating a potential upside of 49.85%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than Nevro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nevro	2 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.93
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has preferable earnings and valuation, NVRO or BVS?

Nevro has higher earnings, but lower revenue than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nevro	$425.17M	0.51	-$92.21M	-$1.89	-3.03
Bioventus	$555.06M	1.46	-$156.23M	-$0.61	-16.41

Which has more risk & volatility, NVRO or BVS?

Nevro has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Is NVRO or BVS more profitable?

Bioventus has a net margin of -7.11% compared to Nevro's net margin of -16.54%. Bioventus' return on equity of 15.61% beat Nevro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nevro	-16.54%	-23.52%	-10.83%
Bioventus	-7.11%	15.61%	4.01%

Summary

Bioventus beats Nevro on 11 of the 18 factors compared between the two stocks.